<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-10T15:28:47Z</responseDate>
  <request identifier="oai:figshare.com:article/34026136" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/34026136</identifier>
        <datestamp>2026-09-29T17:28:28Z</datestamp>
        <setSpec>category_12</setSpec>
        <setSpec>category_21</setSpec>
        <setSpec>category_64</setSpec>
        <setSpec>category_132</setSpec>
        <setSpec>portal_5</setSpec>
        <setSpec>item_type_1</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>&lt;p&gt;PRISMA 2020 flow diagram of study selection.&lt;/p&gt;</dc:title>
          <dc:creator>Yu Xiao (150812)</dc:creator>
          <dc:creator>Jing Fu (177892)</dc:creator>
          <dc:creator>Juan Li (146180)</dc:creator>
          <dc:creator>Gang Hu (132827)</dc:creator>
          <dc:subject>Cell Biology</dc:subject>
          <dc:subject>Biotechnology</dc:subject>
          <dc:subject>Cancer</dc:subject>
          <dc:subject>Infectious Diseases</dc:subject>
          <dc:subject>required summary measures</dc:subject>
          <dc:subject>level summary statistics</dc:subject>
          <dc:subject>grade ae estimates</dc:subject>
          <dc:subject>available regimens differ</dc:subject>
          <dc:subject>analyzed exploratorily using</dc:subject>
          <dc:subject>98 &amp;# 8211</dc:subject>
          <dc:subject>87 &amp;# 8211</dc:subject>
          <dc:subject>80 &amp;# 8211</dc:subject>
          <dc:subject>79 &amp;# 8211</dc:subject>
          <dc:subject>67 &amp;# 8211</dc:subject>
          <dc:subject>06 &amp;# 8211</dc:subject>
          <dc:subject>less favorable pfs</dc:subject>
          <dc:subject>analysis summarized pfs</dc:subject>
          <dc:subject>effect bayesian models</dc:subject>
          <dc:subject>connected overall networks</dc:subject>
          <dc:subject>bayesian network meta</dc:subject>
          <dc:subject>24 &amp;# 8211</dc:subject>
          <dc:subject>19 &amp;# 8211</dc:subject>
          <dc:subject>16 ), ptn</dc:subject>
          <dc:subject>favorable survival profile</dc:subject>
          <dc:subject>xlink "&gt; within</dc:subject>
          <dc:subject>highest confirmed orr</dc:subject>
          <dc:subject>analysis &lt;/ p</dc:subject>
          <dc:subject>indirect survival comparisons</dc:subject>
          <dc:subject>pneumonitis risk relative</dc:subject>
          <dc:subject>dominant survival networks</dc:subject>
          <dc:subject>compared therapies used</dc:subject>
          <dc:subject>xlink "&gt; her2</dc:subject>
          <dc:subject>dm1 vs lap</dc:subject>
          <dc:subject>xlink "&gt;</dc:subject>
          <dc:subject>dominant pfs</dc:subject>
          <dc:subject>confirmed orr</dc:subject>
          <dc:subject>19 ),</dc:subject>
          <dc:subject>pneumonitis networks</dc:subject>
          <dc:subject>targeted therapies</dc:subject>
          <dc:subject>sae comparisons</dc:subject>
          <dc:subject>nala network</dc:subject>
          <dc:subject>july 24</dc:subject>
          <dc:subject>effects models</dc:subject>
          <dc:subject>survival ranking</dc:subject>
          <dc:subject>pneumonitis odds</dc:subject>
          <dc:subject>dominant trials</dc:subject>
          <dc:subject>treatment difference</dc:subject>
          <dc:subject>sparse sae</dc:subject>
          <dc:subject>quantitatively synthesized</dc:subject>
          <dc:subject>prespecified conversion</dc:subject>
          <dc:subject>phase ii</dc:subject>
          <dc:subject>odds ratios</dc:subject>
          <dc:description>&lt;p&gt;Flow diagram showing database identification, removal of 742 duplicates, screening of 2,849 records, full-text assessment of 32 reports, and final inclusion of 16 reports representing seven independent randomized trial families, with detailed reasons and counts for exclusion at each stage.&lt;/p&gt;</dc:description>
          <dc:date>2026-09-29T17:28:10Z</dc:date>
          <dc:type>Image</dc:type>
          <dc:type>Figure</dc:type>
          <dc:identifier>10.1371/journal.pone.0358540.g001</dc:identifier>
          <dc:relation>https://figshare.com/articles/figure/_p_PRISMA_2020_flow_diagram_of_study_selection_p_/34026136</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
